RYE, N.Y., Dec. 18 /PRNewswire/ -- Curemark’s Board of Directors announced today that Steven M. Schwarz, MD, FAAP, FACN, AGAF, will join the company as a senior scientist and will serve on the company’s Scientific Advisory Board. Dr. Schwarz is presently Chairman of the Department of Pediatrics at The Long Island College Hospital and Professor of Pediatrics at the State University of New York Health Science Center at Brooklyn.
“Dr. Schwartz is one of America’s foremost authorities on pediatric gastroenterology,” states Dr. Joan Fallon, Curemark’s CEO. “Having Dr. Schwarz as an integral part of Curemark will assist the company greatly as we prepare for autism clinical trials scheduled for the early part of 2008. His vast expertise in the areas of gastroenterology and developmental disabilities is a perfect fit with Curemark’s research and proprietary work in pediatric dysautonomia, autism and ADHD.”
A graduate of Yale College and Columbia University’s College of Physicians and Surgeons, Dr. Schwarz received his training in Pediatrics and Pediatric Gastroenterology and Nutrition at Columbia and Stanford Universities. Dr. Schwarz served on the faculty of the Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine from 1980-84, and at New York Medical College from 1984-95. At New York Medical College, he was awarded the Charles H. Revson Foundation Career Scientist Award. In 1995 he was named Distinguished Lecturer in the Graduate School of Health Sciences.
Curemark, with offices in Rye, NY, is a drug development company focused on the treatment of neurological and other diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company’s initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of key enzymes in autistic children. She has identified and patented a series of biomarkers that delineate which autistic patients may have digestive deficiencies underlying their disease. Curemark is the first company to deliver upon the connection between a variety of conditions, including autism, ADD/ADHD, Parkinson’s and others that have roots in the gastrointestinal tract. To learn more about our innovative science, visit http://www.Cure-Mark.com.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
CONTACT: Media, Kate Taylor, +1-914-925-3450, or Investors, Ken Nanus,
+1-914-450-0816, both of Curemark
Web site: http://www.Cure-Mark.com/
